Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D. Wiviott, Marc S. Sabatine, Ofri Mosenzon et al.|New England Journal of Medicine|2018Cited by 6.3k
Author response for "Cardiovascular and renal outcomes by baseline albuminuria status and renal function — results from the <scp>LEADER</scp> randomized trial"Ofri Mosenzon, Itamar Raz, Stephen C. Bain et al.|Unknown|2020Cited by 0